Epidural Stimulation in Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

A Pilot Study to Explore the Use of Percutaneous Spinal Stimulation in Participants With Multiple Sclerosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06019611
• Other study ID #: 23-003967
• Status: Recruiting
• Phase: N/A
• Start date: September 11, 2023
• Est. completion date: September 2024

Study information

• Verified date: January 2024
• Source: Mayo Clinic
• Contact: Carol M. Denny
• Phone: 507-422-9337
• Email: denny.carol[@]mayo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to quantify changes in motor performance of epidural stimulation in progressive multiple sclerosis (MS) patients over the course of 12 rehabilitation sessions.

Description:

The purpose of this trial is to study spinal motor nerve response to electrical stimulation delivered directly to the epidural space, and to measure any changes in motor performance during 12 sessions over the course of one month.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• Myelopathy secondary to Progressive MS
• No clinical or radiologic MS relapses for > 5 years
• EDSS score of 6.5 (constant bilateral assistance required to walk about 20 meters without resting) as assessed by a Neurologist with a specialty in MS
• Able to ambulate 10 feet independently with or without gait aid use
• At least 22 years of age
• No changes to spasticity medications or dalfampridine over the last 3 months

Exclusion Criteria:

• Currently a prison inmate, or awaiting trial, related to criminal activity
• Pregnancy at the time of enrollment
• History of chronic and/or treatment resistant urinary tract infection
• Spasticity (grade of 4) measured bilaterally in two muscle groups using Modified Ashworth Scale (MAS). Muscle groups tested will include bilateral knee flexors, extensors; ankle plantarflexors, dorsiflexors
• Unhealed decubitus ulcer
• Unhealed skeletal fracture
• Receiving diathermy treatment
• Active participation in an interventional clinical trial
• Any illness or condition which, based on the research team's assessment, will compromise the patient's ability to comply with the protocol, patient safety, or the validity of the data collected during this study.
• History of coagulopathy or other significant cardiac or medical risk factors for surgery
• Ventilator-dependent respiration
• Diagnosed with cardiopulmonary dysfunction (e.g., chronic obstructive pulmonary disease, cardiac failure, or heart arrhythmia)
• Untreated clinical diagnosis of depression
• History of frequent hypotension characterized by light headedness, or loss of consciousness
• History of frequent hypertension characterized by headache, or bradycardia
• Any active, implanted medical device
• Treatment of chemodenervation and/or neurolysis during the trial, or within 6 months of initiating the trial

Related Conditions & MeSH terms

• Autoimmune Diseases
• Demyelinating Diseases
• Demyelinating Disorder
• Multiple Sclerosis
• Sclerosis

Intervention

Device:
• Percutaneous epidural stimulation
Abbott percutaneous trial lead for epidural neurostimulation (Model 3086) Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874) Ripple Neuromed Nomad Neurostimulation System

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Kristin Zhao, PhD	Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kinematics	Change in measurements of joint angles, measured in degrees.	Through study completion; approximately 4 weeks.
Primary	Kinetics	Change in measurement of movement force and pressure, measured in kilograms	Through study completion; approximately 4 weeks.
Primary	Electromyography (EMG)	Change in voltage measurements in major muscle groups of the lower extremities.	Through study completion; approximately 4 weeks.
Primary	Spasticity (1)	Change in measurements of leg muscle tone utilizing Wartenberg's pendulum test, with tone measured via electromyography.	Through study completion; approximately 4 weeks.
Primary	Spasticity (2)	Change in measurement of leg muscle tone utilizing the Modified Ashworth Scale (MAS). A physical therapist will use a 5-point scale to assess resistance of major muscles during passive range of motion, with a lower score for a muscle indicating less tone.	Through study completion; approximately 4 weeks.
Secondary	Overground ambulation	Measurement of changes in overground mobility as measured by the Timed Up and Go (TUG). Trainers will record the time in seconds in which the subject can stand from a seated position in a chair, traverse 3 meters, turn around, return to the chair, and sit back down. A lower score characterizes better overground mobility.	Through study completion; approximately 4 weeks.
Secondary	Disability	Measurement of changes in patient-reported disability status, utilizing the Short Form (36) Health Survey (SF-36). Questions are numerically ranked, with lower numbers representing more disability. Scores are combined into a composite scale from 0-100, with a score of zero equivalent to maximum disability and a score of 100 equivalent to no disability.	Through study completion; approximately 4 weeks.
Secondary	Fatigue	Measurement of changes in patient-reported fatigue status, utilizing the Modified Fatigue Impact Scale (MFIS). Items are scaled so that higher scores indicate a greater impact of fatigue on a person's activities. The total MFIS score can range from 0 to 84, with a score of zero equivalent to no fatigue and a score of 84 equivalent to maximum fatigue.	Through study completion; approximately 4 weeks.
Secondary	Pain	Measurement of changes in patient-reported pain status, utilizing the Pain Effects Scale (PES). Items are scaled so that higher scores indicate a greater impact of pain on a person's activities. The total PES score can range from 5 to 30, with a score of 5 equivalent to no fatigue and a score of 84 equivalent to maximum fatigue.	Through study completion; approximately 4 weeks.
Secondary	Sexual Satisfaction	Measurement of changes in patient-reported sexual satisfaction, utilizing the Sexual Satisfaction Scale (SSS). Items are scaled so that lower scores indicate a greater degree of satisfaction with aspects of the person's sex life. The total SSS score can range from 4 to 24, with a score of 4 equivalent to extreme satisfaction and a score of 24 equivalent to extreme dissatisfaction.	Through study completion; approximately 4 weeks.
Secondary	Bladder Control	Measurement of changes in patient-reported bladder control, utilizing the Bladder Control Scale (BLCS). Items are scaled so that lower scores indicate a greater degree of bladder control. The total BLCS score can range from 0 to 22, with a score of 0 equivalent to complete bladder control and a score of 22 equivalent to very poor bladder control.	Through study completion; approximately 4 weeks.
Secondary	Bowel Control	Measurement of changes in patient-reported bladder control, utilizing the Bowel Control Scale (BWCS). Items are scaled so that lower scores indicate a greater degree of bowel control. The total BWCS score can range from 0 to 26, with a score of 0 equivalent to complete bowel control and a score of 26 equivalent to very poor bowel control.	Through study completion; approximately 4 weeks.
Secondary	Impact of Visual Impairment	Measurement of changes in patient-reported visual impairment, utilizing the Impact of Visual Impairment Scale (IVIS). Items are scaled so that lower scores indicate less impairment on simple visual tasks. The total IVIS score can range from 0 to 15, with a score of 0 equivalent to no impairment and a score of 15 equivalent to severe visual impairment.	Through study completion; approximately 4 weeks.
Secondary	Cognitive Dysfunction	Measurement of changes in patient-reported cognitive dysfunction, utilizing the Perceived Deficits Questionnaire (PDQ). Items are scaled so that lower scores indicate less cognitive dysfunction. The total PDQ score can range from 0 to 80, with a score of 0 equivalent to no cognitive dysfunction and a score of 80 equivalent to extreme cognitive dysfunction.	Through study completion; approximately 4 weeks.
Secondary	Mental Health	Measurement of changes in patient-reported psychological distress and psychological well-being, utilizing the Mental Health Inventory (MHI). Items are scaled so that higher scores indicate less psychological distress. The raw score range is 38-226, with higher scores equivalent to less psychological distress and greater psychological well-being.	Through study completion; approximately 4 weeks.
Secondary	Social Support	Measurement of changes in patient-reported availability of social support, utilizing the Modified Social Support Survey (MSSS). Items are scaled so that higher scores indicate more social support. The total MSSS score can range from 18 to 90, with a score of 18 equivalent to no social support and a score of 90 equivalent to strong social support.	Through study completion; approximately 4 weeks.

External Links

•   Mayo Clinic Clinical Trials